Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets
Lung cancer is the leading cause of cancer mortality in both genders, with non-small cell lung cancer (NSCLC) accounting for about 85% of all lung cancers. At the time of diagnosis, the tumour is usually locally advanced or metastatic, shaping a poor disease outcome. NSCLC includes adenocarcinoma, s...
Guardado en:
Autores principales: | Khuloud Bajbouj, Abeer Al-Ali, Rakhee K. Ramakrishnan, Maha Saber-Ayad, Qutayba Hamid |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3cb0adb3823548a79aea316663e8384b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
LSD1: Expanding Functions in Stem Cells and Differentiation
por: Carlos Martinez-Gamero, et al.
Publicado: (2021) -
Reprogramming of Histone H3 Lysine Methylation During Plant Sexual Reproduction
por: Huihui Fang, et al.
Publicado: (2021) -
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma
por: Tandon N, et al.
Publicado: (2016) -
Role of HDAC6 and Its Selective Inhibitors in Gastrointestinal Cancer
por: Bingyi Zhou, et al.
Publicado: (2021) -
The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
por: Al-Keilani MS, et al.
Publicado: (2018)